Company & Sponsor Intelligence
SK Life Science, Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed3
Countries1
Therapeutic footprint
epilepsyother_neurology
Indexed studies
NCT03731715Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
other_neurology · United StatesPHASE1
other_neurology · United StatesPHASE1
NCT03678753Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
epilepsy · United StatesPHASE3
epilepsy · United StatesPHASE3
NCT00433667A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
epilepsy · PHASE3
epilepsy · PHASE3
Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →